US and UK Agree to Tariff-Free Arrangement on Medicines.

The United Kingdom and the United States have announced a key bilateral deal that will keep no tariffs on UK drug exports entering the US market.

Key Provisions of the Accord

As part of the deal, the UK has pledged to boost spending on pharmaceuticals through the NHS. This move ensures that tariffs on these crucial products will remain at nothing for a period of 36 months.

This development comes after recent statements to dramatically increase tariffs on patented pharmaceutical products, with increases discussed up to 100%.

"This arrangement between the Britain strengthens the worldwide climate for cutting-edge drugs and introduces long-overdue balance to transatlantic pharmaceutical trade," a release said.

Trade Impact

Drugs constitute one of the the United Kingdom's largest exports to the America, which is clearly the largest destination for leading UK drugmakers.

Trade data reveal that in the year leading up to the third quarter, the UK sold medicines totaling billions to the US. This value made up a significant portion of total UK exports in that timeframe.

"This deal safeguards employment, stimulates funding and paves the way for the UK to establish itself as a worldwide center for biotech and pharma," the Business and Trade Secretary stated.

Key British Pledges

The pact involves several key commitments from the UK:

• Revised Affordability Limit: The UK will lift the affordability limit at which it judges new therapies to be too expensive by 25%.
• Boosted Medicine Funding: There is a aim to double overall health service expenditure on treatments from 0.3% of Gross Domestic Product to 0.6% over the coming ten years.
• Rebate Cap: The sum drug companies must pay back to the NHS to control costs will be limited at 15%. Last year, refunds exceeded 20%.

Broader Context

The deal comes amid a ongoing dispute between the drug companies and the ministers over medicine costs and approval rates.

The disagreement were heightened by claims that US consumers were paying significantly more for the equivalent treatments than consumers in the UK and Europe.

Over the last 18 months, several major drug company projects in the UK have been paused or abandoned, while major funding commitments have been pledged toward American operations.

The Science Minister publicly accepted that the NHS must spend more on treatments, noting that its expenditure on drugs had decreased as a proportion of its total funding over the previous ten-year period.